1 | Cytopathology result | 422463 | Number
[1]
| 1 | Positive | 2 | Negative | 3 | Equivocal | 7 | Not applicable | 9 | Not available |
| |
2 | Lymphovascular invasion indicator | 519212 | Boolean
[1]
| | |
3 | Cervical lymphovascular invasion location | 424175 | Number
[1]
| 1 | Lymphovascular invasion present and at tumour interface | 2 | Lymphovascular invasion present and within cervix remote from tumour interface | 3 | Lymphovascular invasion present (location unknown) | 7 | Not applicable-pathology specimen not obtained or no lymphovascular invasion present | 8 | Unknown whether pathology specimen obtained | 9 | Pathology specimen obtained but lymphovascular invasion not stated/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with cervical cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N, and when Person with cancer—lymphovascular invasion indicator, yes/no code N indicates the presence of lymphovascular invasion. |
4 | Corpus uteri lymphovascular invasion location | 424445 | Number
[1]
| 1 | Lymphovascular invasion present and at tumour interface | 2 | Lymphovascular invasion present and within the myometrium remote to the tumour interface | 3 | Lymphovascular invasion present (location unknown) | 7 | Not applicable-pathology specimen not obtained or no lymphovascular invasion present | 8 | Unknown whether pathology specimen obtained | 9 | Pathology specimen obtained but lymphovascular invasion not stated/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N, and when Person with cancer—lymphovascular invasion indicator, yes/no code N indicates the presence of lymphovascular invasion. |
5 | FIGO cervical cancer stage | 424190 | Number
[2]
| 1 | Stage IA1 | 2 | Stage IA2 | 3 | Stage IB1 | 4 | Stage IB2 | 5 | Stage IIA1 | 6 | Stage IIA2 | 7 | Stage IIB | 8 | Stage IIIA | 9 | Stage IIIB | 10 | Stage IVA | 11 | Stage IVB | 99 | Not available/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with cervical cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. |
6 | FIGO endometrial cancer stage | 424209 | Number
[2]
| 1 | Stage IA | 2 | Stage IB | 3 | Stage II | 4 | Stage IIIA | 5 | Stage IIIB | 6 | Stage IIIC1 | 7 | Stage IIIC2 | 8 | Stage IVA | 9 | Stage IVB | 99 | Not available/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. |
7 | FIGO ovarian cancer stage | 424212 | Number
[2]
| 1 | Stage IA | 2 | Stage IB | 3 | Stage IC1 | 4 | Stage IC2 | 5 | Stage IC3 | 6 | Stage IIA | 7 | Stage IIB | 8 | Stage IIIA1 | 9 | Stage IIIA1(i) | 10 | Stage IIIA1(ii) | 11 | Stage IIIA2 | 12 | Stage IIIB | 13 | Stage IIIC | 14 | Stage IV | 15 | Stage IVA | 16 | Stage IVB | 99 | Not available/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with ovarian cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. |
8 | Distant metastatic site indicator | 545189 | Number
[1]
| 1 | Yes | 2 | No | 9 | Not stated/inadequately described |
| |
9 | Distant metastatic site(s) at diagnosis | 424239 | Number
[2]
| 1 | Lung | 2 | Liver | 3 | Bowel | 4 | Bone | 5 | Brain | 88 | Other | 99 | Metastatic spread indicated but site not stated/inadequately described |
| Conditional obligation: This data element is to be completed if Person with cancer—distant metastatic cancer indicator, yes/no/not stated/inadequately described code N indicates the presence of metastatic cancer. |
10 | Depth of myometrial invasion | 545243 | Number
[2]
| 97 | Not applicable | 98 | Unknown | 99 | Not stated/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. |
11 | Myometrial thickness | 424269 | Number
[2]
| 97 | Not applicable | 98 | Unknown | 99 | Not stated/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with endometrial cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. |
12 | Depth of cervical cancer invasion | 424275 | Number
[2]
| 97 | Not applicable | 98 | Unknown | 99 | Not stated/inadequately described |
| Conditional obligation: This data element is only to be recorded for patients with cervical cancer, as indicated by Person with cancer—primary site of cancer, topography code (ICD-O-3) ANN.N. |
13 | Tumour outside primary site indicator | 545382 | Number
[1]
| 1 | Yes | 2 | No | 9 | Not stated/inadequately described |
| |
14 | Tumour size outside primary site | 424282 | Number
[1]
| 1 | Macroscopic disease less than or equal to 2 cm outside the primary tumour site | 2 | Macroscopic disease between 2 cm and less than 10 cm outside primary tumour site | 3 | Macroscopic disease equal to or greater than 10 cm outside the primary tumour site | 8 | Unknown | 9 | Not stated/inadequately described |
| |
15 | Multiple primary tumours indicator | 519548 | Boolean
[1]
| | |
16 | Multiple primary tumours descriptor | 429482 | Number
[1]
| 1 | Synchronous | 2 | Metachronous | 7 | Not applicable, i.e. single primary tumour only | 8 | Number of primary tumours unknown | 9 | Multiple primary tumours present, but synchronicity not stated/inadequately described |
| Conditional obligation: This data element is to be recorded if Person with cancer—multiple primary tumours indicator, yes/no code N indicates the presence of multiple primary tumours. |
17 | Tissue sample collected indicator | 446565 | Boolean
[1]
| | |
18 | Organisation name | 453823 | String
[200]
| X[X(199)] A combination of alphanumeric characters. | Conditional obligation: This data element is to be recorded when the data element Person—tissue sample collected indicator, yes/no code N indicates that a tissue sample has been collected. DSS specific information: Use this data element to record the name of the laboratory or biobank in which a tissue sample is stored. Collect this data element in conjunction with Person—tissue sample collected indicator, yes/no code N. |
19 | Surgical specialty gynaecological cancer | 424298 | Number
[2]
| 1 | Gynaecological oncologist | 2 | Gynaecologist | 3 | General surgeon | 8 | Other | 98 | Unknown |
| Conditional obligation: This data element is only to be recorded for patients who have undergone surgery relating to their initial course of treatment for gynaecological cancer. |
20 | Tumour residual post-surgery size category | 424302 | Number
[1]
| 1 | Microscopic but no macroscopic residual disease | 2 | Residual tumour less than 0.5 cm | 3 | Residual tumour between 0.5 cm and less than 1 cm | 4 | Residual tumour between 1 cm and 2 cm | 5 | Residual tumour greater than 2 cm | 7 | Not applicable | 8 | Unknown/unable to be assessed | 9 | Not stated/inadequately described |
| Conditional obligation: This data element is to be recorded then the data element Cancer treatment—residual (R) tumour indicator, yes/no code N indicates the presence of residual tumour after surgery. |
21 | Residual tumour indicator | 430267 | Boolean
[1]
| | Conditional obligation: This data element is to be recorded for patients with ovarian cancer and stage IV endometrial cancer when surgical treatment for gynaecological cancer has been completed. |
22 | Surgical treatment complication indicator | 546455 | Number
[1]
| | |
23 | Surgical treatment complication type | 424310 | Number
[2]
| 1 | Unplanned return to theatre | 2 | Death within 30 days of surgery | 3 | Post-operative fistula | 4 | Intra-operative haemorrhage (greater than 6 units of transfusion) | 5 | Pulmonary embolism | 6 | Unplanned transfer to intensive care unit (ICU) | 7 | Post-operative stay greater than 21 days | 88 | Other complication or critical event | 98 | Unknown | 99 | Not stated/inadequately described |
| Conditional obligation: This data element is to be recorded when Cancer treatment—primary surgical treatment complication indicator, yes/no/unknown code N indicates the presence of a treatment complication. |
24 | Radiotherapy treatment complication indicator | 546597 | Number
[1]
| | Conditional obligation: This data element should be recorded in relation to the primary course of treatment for gynaecological cancer. DSS specific information: This relates to the primary course of treatment for gynaecological cancer. |
25 | Radiotherapy treatment complication type | 424314 | Number
[1]
| 1 | Bowel obstruction requiring surgery | 2 | Fistula requiring stoma formation | 3 | Pelvic insufficiency | 8 | Other | 9 | Not stated/inadequately described |
| Conditional obligation: This data element should be recorded when Cancer treatment—gynaecological cancer post-radiotherapy complication indicator, yes/no/unknown code N indicates the presence of a radiotherapy related treatment complication. |
26 | Treatment complication description | 467640 | String
[150]
| X[X(149)] A combination of alphanumeric characters. | Conditional obligation: This data element is to be recorded when either Cancer treatment—treatment complication type, gynaecological cancer-related radiotherapy code N or Cancer treatment—treatment complication type, cancer-related primary surgery complication type code N[N] indicates an 'Other' type of treatment complication. |
27 | Systemic therapy modification indicator | 546764 | Number
[1]
| | Conditional obligation: This data element is to be recorded for patients who have undergone systemic therapy as part of their cancer treatment. This includes chemotherapy, hormone therapy and immunotherapy. |
28 | Systemic therapy modification type | 424306 | String
[2]
| 01 | Dose decrease | 02 | Drug omission | 03 | Drug delivery interval increase | 04 | Dose increase | 05 | Drug introduction | 06 | Drug delivery interval decrease | 07 | Dose increase and interval decrease | 88 | Other | 99 | Not stated/inadequately described |
| Conditional obligation: This data element is to be recorded when Cancer treatment—systemic therapy treatment modification indicator, yes/no/unknown code N indicates a modification to planned systemic therapy treatment. |
29 | Treatment plan modification description | 568890 | String
[150]
| X[X(149)] A combination of alphanumeric characters. | Conditional obligation: This data element is to be recorded when Cancer treatment—treatment modification type for cancer-related systemic therapy, code N[N] indicates an 'Other' type of treatment modification. |
30 | Delay in primary course of chemotherapy indicator | 542950 | Number
[1]
| | Conditional obligation: This data element is to be recorded for patients who have undergone chemotherapy as part of their cancer treatment. |
31 | Primary course of chemotherapy delay reason | 424458 | Number
[1]
| 1 | Delay due to toxicity | 2 | Delay due to other complication | 3 | Delay due to patient decision | 8 | Other | 9 | Not stated/inadequately described |
| Conditional obligation: This data element is to be recorded when Cancer treatment—chemotherapy delay indicator, yes/no/unknown code N indicates a delay in planned chemotherapy treatment. |
32 | Cancer treatment type | 561618 | Number
[2]
| 1 | Surgery only | 2 | Radiotherapy only | 3 | Systemic agent therapy only | 4 | Surgery and radiotherapy | 5 | Surgery and systemic agent therapy | 6 | Radiotherapy and systemic agent therapy | 7 | Surgery, radiotherapy and systemic agent therapy | 97 | Not applicable—treatment was not administered | 98 | Unknown whether treatment was administered | 99 | Treatment was administered but the type was not stated/inadequately described |
| Conditional obligation: This data element is to be recorded for a patient having a first recurrence of cancer. All treatments administered to the patient during the first recurrence of cancer should be recorded. DSS specific information: This data element is to be recorded separately for the primary course of treatment and treatment for the first recurrence of cancer. All treatments administered to the patient as part of the primary course of treatment for the first recurrence of cancer should be recorded. |
33 | Other cancer treatment description | 561623 | String
[150]
| X[X(149)] The cancer-directed treatment administered to the patient that cannot be defined as surgery, radiotherapy or systemic therapy. | Conditional obligation: This data element is to be recorded for a patient having treatment that cannot be defined as surgery, radiotherapy or systemic therapy according to the definitions of those data items in this data set. DSS specific information: This data element is to be used to describe treatment, other than surgery, radiotherapy or systemic therapy, used to treat a first recurrence of gynaecological cancer. |
34 | Outcome of treatment | 561665 | Number
[2]
| 1.0 | Complete response/no evidence of disease | 2.1 | Partial response | 2.2 | Stable or static disease | 2.3 | Progressive disease | 7.0 | Not assessed or unable to be assessed | 8.0 | Unknown | 9.0 | Not stated/inadequately described |
| Conditional obligation: This data element is conditional on a patient completing treatment for their first recurrence of cancer. DSS specific information: This data element is to be recorded for patients who have completed their primary course of treatment or treatment for the first recurrence of cancer. For patients who have completed treatment for their first recurrence of cancer this should be recorded multiple times, once in relation to their primary course of treatment and once in relation to treatment for the first recurrence of cancer. |